CytoDyn (OTCMKTS:CYDY) Stock Sees High Volatility: What’s The Buzz?

August 2, 2021

Late-stage biotechnology company developing innovative treatments for multiple therapeutic indications, CytoDyn (OTCMKTS:CYDY), on August 2, 2021 announced that director nominations done by activist group led by Bruce Patterson and Paul Rosenbaum were invalid. The Rosenbaum/Patterson Group made efforts for nominating five director candidates for taking control of the firm’s Board of Directors.  The company’s bylaws include standard “advance notice bylaw” for shareholder protection, requiring some disclosures by nominating shareholders for…

Read More >>

CytoDyn Inc. (OTCMKTS: CYDY) Releases Leronlimab Results of COVID-19 Long-Haulers Study

July 6, 2021

CytoDyn Inc. (OTCMKTS: CYDY) has announced the initial result following the unblinding of the data from the ongoing long COVID clinical trial.  Leronlimba alleviated COVID-19 symptoms.  The COVID-19 long-haulers study sought to assess the efficacy and safety of leronlimab delivered subcutaneously weekly to subjects showing prolonged COVID-19 symptoms. The study’s primary endpoint was a change from baseline in COVID-19 related symptom severity through the 56th day. Progression of COVID-19-related symptoms…

Read More >>